| 5.09 0.26 (5.38%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.93 | 1-year : | 7.94 |
| Resists | First : | 5.94 | Second : | 6.8 |
| Pivot price | 5.13 |
|||
| Supports | First : | 4.55 | Second : | 3.78 |
| MAs | MA(5) : | 4.94 |
MA(20) : | 5.13  |
| MA(100) : | 4.3 |
MA(250) : | 10.25 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 21.6 |
D(3) : | 20.6 |
| RSI | RSI(14): 49.6 |
|||
| 52-week | High : | 70 | Low : | 2.59 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TTOO ] has closed above bottom band by 46.4%. Bollinger Bands are 29.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.14 - 5.16 | 5.16 - 5.19 |
| Low: | 4.7 - 4.72 | 4.72 - 4.74 |
| Close: | 5.05 - 5.08 | 5.08 - 5.12 |
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Tue, 23 Jul 2024
T2 Biosystems (NASDAQ:TTOO) Shares Pass Below 50 Day Moving Average of $5.19 - Defense World
Mon, 22 Jul 2024
T2 Biosystems to Report Second Quarter 2024 Financial Results and Business Updates on July 29, 2024 - GlobeNewswire
Mon, 22 Jul 2024
T2 Biosystems to Report Second Quarter 2024 Financial Results and Business Updates on July 29, 2024 - StockTitan
Mon, 15 Jul 2024
Short Interest in T2 Biosystems, Inc. (NASDAQ:TTOO) Expands By 32.0% - Defense World
Wed, 22 May 2024
T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements - Yahoo Finance
Wed, 15 May 2024
T2 Biosystems Announces $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 17 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 2.4 (%) |
| Held by Institutions | 70.7 (%) |
| Shares Short | 417 (K) |
| Shares Short P.Month | 291 (K) |
| EPS | 109.91 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -6.85 |
| Profit Margin | 0 % |
| Operating Margin | -611.4 % |
| Return on Assets (ttm) | -100.2 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -0.9 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.42 |
| EBITDA (p.s.) | -2.66 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -47 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | 0.04 |
| PEG Ratio | 0 |
| Price to Book value | -0.75 |
| Price to Sales | 12.1 |
| Price to Cash Flow | -1.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|